Text Size

Study of Amifostine and IMRT for Protecting Salivary Glands in Head and Neck Cancer

This study has been completed.
Sponsor:
Information provided by:
Washington University School of Medicine
ClinicalTrials.gov Identifier:
NCT00167908
First received: September 9, 2005
Last updated: February 3, 2009
Last verified: February 2009
History of Changes
  Purpose

The purpose of this study is to determine whether Amifostine provides additional protection of salivary gland function over that achieved with IMRT alone.


Condition Intervention Phase
Head and Neck Cancer
 Drug: Ethyol (drug)
 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pilot Study to Test Whether Amifostine Can Further Protect Salivary Function in Head and Neck Cancer Patients Treated With IMRT

Resource links provided by NLM:

Drug Information available for: Amifostine
U.S. FDA Resources

Further study details as provided by Washington University School of Medicine:

Primary Outcome Measures:
  • Salivary function at 6 months and yearly compared to pre-treatment salivary function

Secondary Outcome Measures:
  • Local and regional tumor control

Estimated Enrollment: 27
Study Start Date: October 2001
Study Completion Date: May 2007
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pathologically confirmed squamous cell cancer of the head and neck
  • Eligible sites: oral cavity, oropharynx, hypopharynx, larynx.
  • Patients requiring postoperative IMRT.
  • KPS > 70%.
  • Patient has signed specific protocol consent prior to registration.
  • Calcium test within normal limits.
  • No previous malignancy except for non-melanoma skin cancer or cancer not of head and neck and controlled for at least 5 years.
  • Labs completed with 30 days of registration (CBC & platelet, Ca++, Alk phos, SGOT, Bili, albumin) CXR and CT simulation.
  • Liver CT if alk phos, SGOT, or bili elevated.
  • Bone scan if elevated alk phos

Exclusion Criteria:

  • Metastatic disease.
  • Patient using Salagen or concurrent chemotherapy.
  • Previous XRT for head and neck tumors.
  • Active untreated infection.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00167908

Sponsors and Collaborators
Washington University School of Medicine
Investigators
Principal Investigator: Wade Thorstad, M.D. Washington University Medical Center
  More Information

No publications provided

Responsible Party: Wade Thorstad, MD, Washington University
ClinicalTrials.gov Identifier: NCT00167908     History of Changes
Other Study ID Numbers: ETH018-01D, HSC 00-0885
Study First Received: September 9, 2005
Last Updated: February 3, 2009
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Head and Neck Neoplasms
Neoplasms by Site
Neoplasms
Amifostine
 Radiation-Protective Agents
Protective Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on June 18, 2013